CN1524535A - Nanometer medicine for treating gastritis and gastric ulcer - Google Patents
Nanometer medicine for treating gastritis and gastric ulcer Download PDFInfo
- Publication number
- CN1524535A CN1524535A CNA031442730A CN03144273A CN1524535A CN 1524535 A CN1524535 A CN 1524535A CN A031442730 A CNA031442730 A CN A031442730A CN 03144273 A CN03144273 A CN 03144273A CN 1524535 A CN1524535 A CN 1524535A
- Authority
- CN
- China
- Prior art keywords
- nanometer
- gastric ulcer
- medicine
- ulcer disease
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a nano medicine for treating gastritis and gastric ulcer, which comprises nanometer silver group antibiotic powder and nanometer level magnesium silicate lithium (also called smectite), wherein the content of nanometer silver group antibiotic powder is 0.00005%-95% (silver content 2-20%), the content nanometer level magnesium metasilicate lithium is 5%-99.99995%. The preparation can be in the dosage form of tablet and capsule, its effects include making ulcer surface assimilate fast, isolating irritation and acting as antacid.
Description
Technical field
The invention belongs to medicine, particularly a kind of nanometer medicine for the treatment of gastritis, gastric ulcer disease.
Technical background
Gastric ulcer, gastritis are comparatively obstinate diseases occurred frequently and multiple, and it has caused extreme pain so that catastrophic consequence for people's life.Modern medicine study proves that already the former act of violence of this disease is a helicobacter pylori.Helicobacter pylori not only directly causes gastritis, gastric ulcer, but also brings out the relevant lymph lymphatic cancer with gastric mucosa of gastric cancer.And aspect treatment, use chemical agent, antibiotic and protective agent thereof etc. usually.Modern medicine study proves: have 50% to carry disease germs among the crowd, wherein 10% has clinical symptoms, and these bacterium are external all very sensitive to many antibiotic, but in vivo because the influence of enzyme and gastric acid, its effective percentage only is 0%-20%, and also there is toxic and side effects to some extent in these medicines, and some also can produce new stimulation to stomach.Usually in treatment, the medicine of the good and energy quickly-healing ulcer surface of the patient is badly in need of nontoxic, non-stimulated, no sensitization and anti-bactericidal property.Obviously, existing medicine can not satisfy this demand.
Summary of the invention
The purpose of this invention is to provide be tool anti-, kill helicobacter pylori and protection gastric mucosa, anti-antacid stimulate, the effect of quickly-healing ulcer surface, it is good enough and bring the treatment gastritis of toxic and side effects, the nanometer medicine of gastric ulcer disease to solve existing curative effect of medication again.
As follows for realizing the technical scheme that purpose of the present invention adopts:
A kind of nanometer medicine for the treatment of gastritis, gastric ulcer disease, it includes nanometer silver is antibiotic powder and nanoscale silicic acid magnesium lithium (also claiming smectite); With its percentage by weight is benchmark, and wherein nanometer silver is antibiotic powder (silver content 2-20%) 0.00005%-95%, nanoscale silicic acid magnesium lithium 5%-99.99995%.
Its weight percent proportioning is that nanometer silver is antibiotic powder 5%, nanoscale silicic acid magnesium lithium 95%.Or its weight percent proportioning is that nanometer silver is antibiotic powder 95%, nanoscale silicic acid magnesium lithium 5%.Adding behind the adjuvant its percentage by weight in its prescription, to be assigned as nanometer silver be antibiotic powder (silver content 2-20%) 0.00005%-90%, nanoscale silicic acid magnesium lithium 5%-90.99995%, adjuvant 5%-10%.Its nanometer silver is that the particle diameter of antibiotic powder and nanoscale silicic acid magnesium lithium is the 1-100 nanometer.Its pharmaceutic adjuvant is magnesium stearate, sucrose or starch slurry.Its goods are tablet or capsule formulation.Its starch slurry replaces with dextrin, mucilage or cellulose derivative binding agent.Add correctives in the above-mentioned goods.Its correctives is sugar, essence and other food correctivess or other sweeting agent.
Adopt that employed nanometer silver is that antibiotic powder and nanoscale silicic acid magnesium lithium are confirmed through scientific experiments in the nanometer medicine of treatment gastritis that technical scheme of the present invention makes, gastric ulcer disease: the nanometer silver in its medicine is that antibiotic powder is good anti-antibacterial, it had not both had medicine source property toxic and side effects, can not produce the drug resistance problem yet, be not subjected to the influence of enzyme and gastric acid, so that it kills the effect of helicobacter pylori is better than other drug yet.Employed nanoscale silicic acid magnesium lithium has quick dissolving in its medicine medicine, coated is in gastric mucosa rapidly, and the isolated effect that stimulates also plays the effect of antacid.This medicine has more significant effect and superiority owing to avirulence, non-stimulated, no sensitization and the anti-effective and protection gastric mucosa of helicobacter pylori that kills so have medicine and health product now, and its market prospect is more extensive.
The specific embodiment
The invention will be further described below in conjunction with preferred embodiment.
Embodiment 1: the capsule of preparation treatment gastric ulcer, gastritis.
(1) low dosage prescription: its capsule component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 0.00005%, nanoscale silicic acid magnesium lithium 99.99995%.
(2) dose prescription in: its capsule component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 5%, nanoscale silicic acid magnesium lithium 95%.
(3) high dose prescription: its capsule component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 95%, nanoscale silicic acid magnesium lithium 5%.
Its preparation method is: with the batching difference mixing of above-mentioned each prescription, be respectively charged in No. 1 capsule and make low dosage, middle dosage, high dose capsule according to labelled amount grammes per square metre (every 0.3 gram).Two of low dosage, middle dose capsule per day for adults.One of high dose capsule per day for adults.
Embodiment 2: the high dose tablet of preparation treatment gastric ulcer, gastritis.
(1) low dosage prescription: its tablet component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 0.00005%, nanoscale silicic acid magnesium lithium 92.99995%, sucrose 3%, starch slurry (10%) 3%, magnesium stearate 1%.
(2) dose prescription in: its tablet component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 5%, nanoscale silicic acid magnesium lithium 88%, sucrose 3.5%, starch slurry (10%) 3%, magnesium stearate 0.5%.
(3) high dose prescription: its tablet component and content are that nanometer silver is an antibiotic powder (silver content is 6%) 88%, nanoscale silicic acid magnesium lithium 5%, sucrose 3%, starch slurry (10%) 2%, magnesium stearate 2%.
Its preparation method: earlier with above-mentioned each component except that starch slurry and magnesium stearate and prescription difference mix homogeneously, and then adding starch slurry, use the mixer mix homogeneously, sieve and make wet granular, this granule is through 50-60 ℃ of drying, and above-mentioned technical process is controlled within 4 hours and finishes.Get final product with the tablet machine tabletting behind the magnesium stearate of above-mentioned prescription of adding and component and the mix homogeneously behind the process granulate.Restrain into low dosage, middle dosage, high dose tablet according to labelled amount grammes per square metre 0.3.Two of low dosage, middle dosage tablet per day for adults.One of high dose tablet per day for adults.
In the above-mentioned prescription, starch slurry can replace with other binding agents, as: dextrin, mucilage, cellulose derivative.The cellulose derivative sodium carboxymethyl cellulose.
In the above-mentioned prescription, according to people's taste adding sugar or essence and other food correctivess.
Nanometer silver in its medicine of the present invention is that antibiotic powder is good anti-antibacterial, so that it kills the effect of helicobacter pylori is better than other drug.Employed nanoscale silicic acid magnesium lithium has quick dissolving in its medicine medicine, coated completely cuts off the effect that stimulates and play antacid in gastric mucosa rapidly.Therefore, treatment gastritis, diarrhoea, colitis and functional colonic disorders there is specially good effect.
The above only is preferred embodiment of the present invention, and every foundation technical spirit of the present invention all still belongs in the scope of technical solution of the present invention any simple modification, equivalent variations that above embodiment did.
Claims (10)
1, a kind of nanometer medicine for the treatment of gastritis, gastric ulcer disease, it includes nanometer silver is antibiotic powder and nanoscale silicic acid magnesium lithium (also claiming smectite); With its percentage by weight is benchmark, and wherein nanometer silver is antibiotic powder (silver content 2-20%) 0.00005%-95%, nanoscale silicic acid magnesium lithium 5%-99.99995%.
2, the nanometer medicine of treatment gastritis according to claim 1, gastric ulcer disease is characterized in that: the preferable nanometer silver that is assigned as of its percentage by weight is antibiotic powder 5%, nanoscale silicic acid magnesium lithium 95%.
3, the nanometer medicine of treatment gastritis according to claim 1 and 2, gastric ulcer disease is characterized in that: it is antibiotic powder 95% that its percentage by weight also can be assigned as nanometer silver, nanoscale silicic acid magnesium lithium 5%.
4, the nanometer medicine of treatment gastritis according to claim 1, gastric ulcer disease, it is characterized in that: adding behind the adjuvant its percentage by weight in the above-mentioned prescription, to be assigned as nanometer silver be antibiotic powder (silver content 2-20%) 0.00005%-90%, nanoscale silicic acid magnesium lithium 5%-90.99995%, adjuvant 5%-10%.
5, according to the nanometer medicine of claim 1 or 4 described treatment gastritis, gastric ulcer disease, it is characterized in that: its nanometer silver is that the particle diameter of antibiotic powder and nanoscale silicic acid magnesium lithium is the 1-100 nanometer.
6, the nanometer medicine of treatment gastritis according to claim 4, gastric ulcer disease is characterized in that: its pharmaceutic adjuvant is magnesium stearate, sucrose or starch slurry.
7, the nanometer medicine of treatment gastritis according to claim 1, gastric ulcer disease is characterized in that: its goods are capsule formulation.
8, the nanometer medicine of treatment gastritis according to claim 4, gastric ulcer disease is characterized in that: its goods are tablet form.
9, the nanometer medicine of treatment gastritis according to claim 4, gastric ulcer disease is characterized in that: its starch slurry replaces with dextrin, mucilage or cellulose derivative binding agent.
10, the nanometer medicine of treatment gastritis according to claim 1, gastric ulcer disease is characterized in that: add sugar, essence and food correctives in the above-mentioned goods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031442730A CN1524535A (en) | 2003-09-15 | 2003-09-15 | Nanometer medicine for treating gastritis and gastric ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031442730A CN1524535A (en) | 2003-09-15 | 2003-09-15 | Nanometer medicine for treating gastritis and gastric ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1524535A true CN1524535A (en) | 2004-09-01 |
Family
ID=34286598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031442730A Pending CN1524535A (en) | 2003-09-15 | 2003-09-15 | Nanometer medicine for treating gastritis and gastric ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1524535A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316044A (en) * | 2013-06-07 | 2013-09-25 | 逢甲大学 | Composition structure used for inhibiting gastrointestinal bacterial infections |
| CN104758342A (en) * | 2015-04-02 | 2015-07-08 | 牛太贵 | Capsule for preventing and treating gastroenteritis employing sliver fiber |
-
2003
- 2003-09-15 CN CNA031442730A patent/CN1524535A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316044A (en) * | 2013-06-07 | 2013-09-25 | 逢甲大学 | Composition structure used for inhibiting gastrointestinal bacterial infections |
| CN103316044B (en) * | 2013-06-07 | 2015-11-04 | 逢甲大学 | For suppressing the compositions structure of intestines and stomach bacteriological infection |
| CN104758342A (en) * | 2015-04-02 | 2015-07-08 | 牛太贵 | Capsule for preventing and treating gastroenteritis employing sliver fiber |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5023245A (en) | Improved niacin formulation | |
| CA1333997C (en) | Cholesterol-lowering combination compositions of guar gum and niacin | |
| JP6202547B2 (en) | Oral formulation of bipolar trans carotenoid | |
| CN102391389B (en) | Colloidal bismuth pectin compound and medicinal composition thereof, and preparation methods and application thereof | |
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| EP2262535B1 (en) | Use of a composition containing healing earth as an antacid | |
| CN1524535A (en) | Nanometer medicine for treating gastritis and gastric ulcer | |
| CN116036123A (en) | Compound montmorillonite granule for treating helicobacter pylori infection and preparation method thereof | |
| DE102008059070B4 (en) | A composition for the therapeutic or prophylactic treatment of diarrheal diseases and / or for the maintenance and / or restoration of the natural intestinal flora, dosage unit, packaging unit and use of the composition | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101023961B (en) | Medicine composition containing sodium hyaluronate and zinc salt | |
| CN101703521B (en) | Application of montmorillonite in preparing drugs | |
| CN101028281B (en) | Nano-gel pectin bismuth and its granules medicine | |
| CN101125147B (en) | Glucosamine calcium medicine preparation, preparation method and application thereof | |
| CN1028485C (en) | Compound xidi iodine sucked tablet and its making method | |
| CN105193840B (en) | A kind of kaolin suspension for treating chronic diarrhea and preparation method thereof | |
| AU749509B2 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| Laudato et al. | Natural products of mineral origin | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| WO2021068459A1 (en) | Suspension containing low methoxylation pectin and montmorillonite for treating acute diarrhea | |
| CN102698280B (en) | Tagatose tablet excipient, medicinal tablet and preparation method of medicinal tablet | |
| JPS6072817A (en) | Improvement of iron (11) salt, zinc salt, magnesium salt salt and mixed salt of them as substitute of iron, zinc and magnesium | |
| CN100473392C (en) | Compound clore basil preparation | |
| CN106860411A (en) | A kind of new pharmaceutical preparation colloidal bismmth pectin piece | |
| JP2021187858A (en) | Pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |